Jci_page_head_homepage_01 Jci_page_head_homepage_02
Barbara Bedogni, James A. Warneke, Brian J. Nickoloff, Amato J. Giaccia, Marianne Broome Powell
Published in Volume 118, Issue 11
J Clin Invest. 2008; 118(11):3660–3670 doi:10.1172/JCI36157
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 2
Notch1-NIC expression is a function of PI3K/Akt pathway activation and is transcriptionally regulated by Akt.

(A) We analyzed 26 low-passage melanoma cell lines for activation of the PI3K/Akt and Raf/MEK/Erk pathways with respect to normal human melanocytes in correlation with Notch1-NIC. M, melanocytes; p-, phosphorylated; t-, total. (B) Two of the cell lines analyzed in A (WM266, lane 3; K457, lane 8) were treated with 50 μM Ly294002, 10 μM U0126, or the combination (Ly/U). Effectiveness of the treatment was assessed as the inhibition of phosphorylation of Akt and Erk1/2. (C) K457 and WM266 expressing dominant-negative PI3K (Δp85) were assessed for Notch1-NIC protein. (D) Mouse melanocytes overexpressing oncogenic Akt or oncogenic BRaf were assessed for Notch1-NIC expression. The ratio of Notch1-NIC to α-tubulin was 1.3 for Babe, 4.8 for Akt, and 1.2 for BRaf. (E) Western blot for TM-Notch1 showed higher expression in Akt-expressing cells. (F) qRT-PCR for Notch1. As an internal control, 18S was used for normalization. (G) Notch1 activity, measured as induction of a HES1-dependent reporter construct. Data in F and G are mean ± SD. *P < 0.05 versus Babe control, Student’s t test. In AE, α-tubulin and β-actin were used as indicated as loading controls.